AAP News Vol. 13 No. 2 February 1997, p. 1
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hegland, A.
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Two high-risk infant groups targeted for RSV-IGIV therapy

Anne Hegland

In the absence of a proven effective antiviral therapy for respiratory syncytial virus (RSV) infection prevention, the AAP Committee on Infectious Disease (COID) has targeted two primary categories of high risk infants as candidates for passive immunoprophylaxis using immune globulin intravenously (IGIV).

The two categories are:

• infants and children younger than 2 years with bronchopulmonary dysplasia (BPD) who are currently receiving or have received oxygen therapy within the six months prior to the anticipated RSV season; and

• infants with a gestational age of 32 weeks or less without BPD or who do not meet the criteria in recommendation one, but may also have a major risk factor.